A Randomized, Double-Blind, Controlled Trial of the 17D Yellow Fever Virus Vaccine Given in Combination with Immune Globulin or Placebo: Comparative Viremia and Immunogenicity
Authors:
- Srilatha EdupugantiSESrilatha Edupuganti
- Rachel B. EidexRERachel B. Eidex
- Harry KeyserlingHKHarry Keyserling
- Rama S. AkondyRARama S. Akondy
- Robert LanciottiRLRobert Lanciotti
- Walter OrensteinWOWalter Orenstein
- Carlos del RioCRCarlos del Rio
- Yi PanYPYi Pan
- Troy QuerecTQTroy Querec
- Harvey LipmanHLHarvey Lipman
- Alan BarrettABAlan Barrett
- Rafi AhmedRARafi Ahmed
- 9 January 2013
- journal article
- research article
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 88 (1) , 172-177
Abstract
We evaluated whether coadministration of the yellow fever (YF) virus vaccine with human immunoglobulin (Ig) that contained YF virus-neutralizing antibodies would reduce post-vaccination viremia without compromising immunogenicity and thus, potentially mitigate YF vaccine-associated adverse events. We randomized 80 participants to receive either YF vaccine and Ig or YF vaccine and saline placebo. Participants were followed for 91 days for safety and assessments of viremia and immunogenicity. There were no differences found between the two groups in the proportion of vaccinated participants who developed viremia, seroconversion, cluster of differentiation (CD)-8+ and CD4+ T-cell responses, and cytokine responses. These results argue against one putative explanation for the increased reporting of YF vaccine side effects in recent years (i.e., a change in travel clinic practice after 1996 when hepatitis A prophylaxis with vaccine replaced routine use of pre-travel Ig, thus potentially removing an incidental YF vaccine-attenuating effect of anti-YF virus antibodies present in Ig) (ClinicalTrials.gov identifier: NCT00254826).Keywords
This publication has 28 references indexed in Scilit:
- The Yellow Fever Virus Vaccine Induces a Broad and Polyfunctional Human Memory CD8+ T Cell ResponseThe Journal of Immunology, 2009
- Evaluation of Chimeric Japanese Encephalitis and Dengue Viruses for Use in Diagnostic Plaque Reduction Neutralization TestsClinical and Vaccine Immunology, 2009
- Yellow fever vaccine — how does it work and why do rare cases of serious adverse events take place?Current Opinion in Immunology, 2009
- Adverse event reports following yellow fever vaccinationVaccine, 2008
- Case of Yellow Fever Vaccine–Associated Viscerotropic Disease with Prolonged Viremia, Robust Adaptive Immune Responses, and Polymorphisms in CCR5 and RANTES GenesThe Journal of Infectious Diseases, 2008
- Human Effector and Memory CD8+ T Cell Responses to Smallpox and Yellow Fever VaccinesImmunity, 2008
- Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunityJournal of Experimental Medicine, 2006
- Yellow fever vaccine: An updated assessment of advanced age as a risk factor for serious adverse eventsVaccine, 2005
- Advanced Age a Risk Factor for Illness Temporally Associated with Yellow Fever VaccinationEmerging Infectious Diseases, 2001
- Examination of the envelope glycoprotein of yellow fever vaccine viruses with monoclonal antibodiesVaccine, 1989